| Human chimeric antigen receptor macrophages for cancer immunotherapy M Klichinsky, M Ruella, O Shestova, XM Lu, A Best, M Zeeman, ... Nature biotechnology 38 (8), 947-953, 2020 | 875 | 2020 |
| Checkpoint blockade reverses anergy in IL-13Rα2 humanized scFv-based CAR T cells to treat murine and canine gliomas Y Yin, AC Boesteanu, ZA Binder, C Xu, RA Reid, JL Rodriguez, DR Cook, ... Molecular Therapy-Oncolytics 11, 20-38, 2018 | 148 | 2018 |
| Nucleic acid recognition orchestrates the anti-viral response to retroviruses S Stavrou, K Blouch, S Kotla, A Bass, SR Ross Cell host & microbe 17 (4), 478-488, 2015 | 72 | 2015 |
| Different Modes of Retrovirus Restriction by Human APOBEC3A and APOBEC3G In Vivo S Stavrou, D Crawford, K Blouch, EP Browne, RM Kohli, SR Ross PLoS Pathogens 10 (5), e1004145, 2014 | 62 | 2014 |
| DDX41 Recognizes RNA/DNA Retroviral Reverse Transcripts and Is Critical for In Vivo Control of Murine Leukemia Virus Infection S Stavrou, AN Aguilera, K Blouch, SR Ross MBio 9 (3), 10.1128/mbio. 00923-18, 2018 | 57 | 2018 |
| In Vivo Examination of Mouse APOBEC3- and Human APOBEC3A- and APOBEC3G-Mediated Restriction of Parvovirus and Herpesvirus Infection in Mouse Models Y Nakaya, S Stavrou, K Blouch, P Tattersall, SR Ross Journal of virology 90 (17), 8005-8012, 2016 | 37 | 2016 |
| Deaminase-Dead Mouse APOBEC3 Is an In Vivo Retroviral Restriction Factor S Stavrou, W Zhao, K Blouch, SR Ross Journal of Virology 92 (11), 10.1128/jvi. 00168-18, 2018 | 23 | 2018 |
| DDX41 recognizes RNA/DNA retroviral reverse transcripts and is critical for in vivo control of murine leukemia virus infection. mBio 9: e00923-18 S Stavrou, AN Aguilera, K Blouch, SR Ross View Article: Google Scholar: PubMed/NCBI, 2018 | 6 | 2018 |
| Open-label pilot study of genetically engineered NY-ESO-1–specific t cells (GSK3377794) alone or in combination with pembrolizumab in relapsed/refractory multiple myeloma. A Rapoport, JE Hoffman, JL Kaufman, K Blouch, E Butler, MP Deyoung, ... Journal of clinical oncology 38 (15_suppl), TPS8555-TPS8555, 2020 | 3 | 2020 |
| Open-label pilot study of genetically engineered NY-ESO-1 specific T cells (GSK3377794) alone or in combination with pembrolizumab in relapsed and refractory multiple myeloma T Nishihori, JL Kaufman, JE Hoffman, K Blouch, S Pandit, E Butler, A Jain, ... Blood 134, 3134, 2019 | 2 | 2019 |
| Open-label pilot study of genetically engineered NY-ESO-1 specific T cells (GSK3377794) alone or in combination with pembrolizumab in relapsed and refractory multiple myeloma T Nishihori, JL Kaufman, JE Hoffman, K Blouch, S Pandit, E Butler, A Jain, ... Biology of Blood and Marrow Transplantation 26 (3), S269-S270, 2020 | 1 | 2020 |
| Whole-exome RNA sequencing of metastatic synovial sarcomas reveals heterogeneous transcriptomic profile and targetable co-alterations: Cohort study from the French Sarcoma Group H Vanacker, M Brahmi, YL Meitour, J Bollard, V Attignon, A Meurgey, ... Cancer Research 83 (7_Supplement), 6071-6071, 2023 | | 2023 |
| 1503P Prevalence and clinical characteristics of metastatic synovial sarcoma (mSS) patients with tumours expressing NY-ESO-1 antigen (NY+) and who are HLA-A* 02: 01,* 02: 05 or … A Dufresne, A Meurgey, S Chabaud, J Bollard, M Jean-Denis, L Tonon, ... Annals of Oncology 33, S1234, 2022 | | 2022 |
| Study design of a global molecular disease characterization initiative (MDCI) in oncology clinical trials. D Downs, R Weker, ML Johnson, AG Sacher, MO Butler, HM Zarour, ... Journal of Clinical Oncology 40 (16_suppl), e13598-e13598, 2022 | | 2022 |
| 390 A global, molecular disease characterization initiative (MDCI) in oncology clinical trials M Johnson, A Sacher, M Butler, H Zarour, J Weber, E Garon, D Carbone, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | | 2021 |
| 454 Analysis of NY-ESO-1 expression in specimens from a Phase I/II NY-ESO-1 T-cell therapy clinical trial in non-small cell lung cancer and from exploratory studies in multiple … B Barnes, M Shan, K Blouch, M Altan, J Kim, N Ramos-Hernandez, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | | 2021 |
| 109P A novel, comprehensive glimpse at NY-ESO-1 expression, mRNA to protein translation, & potential impact on clinical studies K Blouch, A Hamilton, J Kim, N Dewal, G Kapoor, S Brett, I Eleftheriadou Annals of Oncology 32, S403, 2021 | | 2021 |
| Human chimeric antigen receptor (CAR) macrophages for cancer immunotherapy. M Klichinsky, M Ruella, O Shestova, A Best, K Blouch, XM Lu, ... CANCER IMMUNOLOGY RESEARCH 8 (4), 29-30, 2020 | | 2020 |
| Abstract PR07: Human chimeric antigen receptor (CAR) macrophages for cancer immunotherapy M Klichinsky, M Ruella, O Shestova, A Best, K Blouch, XM Lu, ... Cancer Immunology Research 8 (4_Supplement), PR07-PR07, 2020 | | 2020 |
| DDX41 recognizes RNA/DNA retroviral reverse transcripts and is critical forin vivocontrol of MLV infection S Stavrou, A Aguilera, K Blouch, SR Ross | | 2018 |
